GlaxoSmithKline Files Its New Pre-Pandemic Influenza Vaccine In Europe

Tue, 30 Jan 2007 02:00 PM EST

... GlaxoSmithKline (NYSE: GSK) today announced that its new generation H5N1 split antigen pre-pandemic influenza vaccine has been accepted for review by the Committee for Medicinal Products for Human Use (CHMP) in Europe. This innovative vaccine utilizes GSK's novel proprietary adjuvant system technology which allows a very low amount of antigen (3. [click link for full article] ...